High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -42.86% and +9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Broker Signals On Veeva Systems Stock A fresh wave of brokerage opinions on Veeva Systems (VEEV) has put the stock back in focus for investors, as firms update their views using earnings estimate revisions and quantitative rating models. These ratings and the underlying Zacks Rank approach do not guarantee any outcome for Veeva Systems investors. They do, however, give you a structured way to compare fresh earnings expectations with the company’s recent share price moves. See our latest...
Based on the average brokerage recommendation (ABR), Veeva (VEEV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $217.8, denoting a +2.01% move from the preceding trading day.
Privia Health (PRVA) delivered earnings and revenue surprises of -12.50% and +8.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Fundsmith, an investment management firm based in London, has released its second-quarter 2026 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here. The Fund returned -2.9% in the first half of 2026, underperforming the MSCI World Index by 14.1 percentage points, driven by challenges from a momentum-driven market […]
From commerce to culture, software is digitizing every aspect of our lives. This secular theme has materialized in superior earnings growth and stock price performance for most SaaS companies, and over the last six months, the industry’s 13.5% return has topped the S&P 500 by 8.6 percentage points.
The latest trading day saw Veeva Systems (VEEV) settling at $201.56, representing a -3.05% change from its previous close.
Investment management company Vulcan Value Partners recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Vulcan Value Partners prioritizes long-term returns and lower risk over short-term performance. In the quarter, the Large Cap Composite (Net) returned 9.5%, the Small Cap Composite (Net) returned 13.3%, the Focus Composite (Net) returned 10.4%, the […]
Veeva Systems (VEEV) is back in focus after the company lifted its fiscal 2027 guidance and signaled higher expected revenue and adjusted EPS, putting upcoming Q2 2027 results firmly on investor radar. See our latest analysis for Veeva Systems. At a share price of US$186.24, Veeva Systems has seen short term momentum pick up, with a 1 month share price return of 15.43% and a 3 month share price return of 15.58%. However, the 1 year total shareholder return is down 35.87%, suggesting the...
Veeva Systems stock has fallen 44.0% over the past five years, yet the latest Discounted Cash Flow (DCF) intrinsic value estimate suggests the current US$186.24 share price sits at a meaningful discount. This creates a clear tension between past returns and what the valuation work implies today. The 44.0% decline over five years means long term shareholders have seen substantial value eroded, so any current valuation upside case needs to be weighed against that track record. Expectations for...
Veeva Systems recently raised its fiscal 2027 revenue guidance to about US$3.65 billion and adjusted EPS outlook to roughly US$9.05, following fiscal Q1 2027 results that exceeded its own guidance and showed stronger profitability helped by expanding AI-driven offerings. This combination of upgraded full-year targets and growing AI-enabled products has sharpened investor focus on how Veeva’s business model may be evolving toward higher-margin, software-driven growth. With Veeva lifting its...
Veeva Systems is scheduled to post its second-quarter results soon, and analysts project a double-digit earnings growth.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
In the closing of the recent trading day, Veeva Systems (VEEV) stood at $179.58, denoting a -2.69% move from the preceding trading day.
According to the average brokerage recommendation (ABR), one should invest in Veeva (VEEV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Recently, Zacks.com users have been paying close attention to Veeva (VEEV). This makes it worthwhile to examine what the stock has in store.
Investing.com -- Cash balances of U.S. companies swelled in the first quarter of 2026, with most companies aggressively deploying money back into their businesses, according to Morgan Stanley.
Veeva Systems (VEEV) concluded the recent trading session at $195.38, signifying a -1.01% move from its prior day's close.
VEEV's strong Q1, growing Vault CRM migrations and AI expansion support growth, though life sciences CRM market saturation poses risks.
The latest trading day saw Veeva Systems (VEEV) settling at $193.09, representing a -1.89% change from its previous close.
Don't give up on these stocks yet.
Veeva Systems (VEEV) is drawing fresh attention after being removed from several Russell growth indices. This shift coincides with solid recent earnings trends and a mixed share price performance this year. See our latest analysis for Veeva Systems. The recent index removals come after a strong rebound in the stock, with a 30 day share price return of 13.13% and a 90 day gain of 25.27%. However, this contrasts with a year to date share price decline of 13.57% and a 1 year total shareholder...
Veeva Systems (NYSE:VEEV) has introduced Veeva EHS, a new environmental, health, and safety application within its Quality Cloud suite. The application is designed to provide an automated, unified platform for managing EHS processes across manufacturing and testing operations. An early adopter rollout is planned for August 2026, targeting life sciences and manufacturing customers that rely on Veeva's quality and compliance tools. For investors following Veeva Systems, Veeva EHS extends the...
Veeva Systems has gotten torched over the last six months - since January 2026, its stock price has dropped 21.7% to $187.94 per share. This may have investors wondering how to approach the situation.
Veeva Systems (VEEV) concluded the recent trading session at $188.17, signifying a -2.15% move from its prior day's close.
Recently, Zacks.com users have been paying close attention to Veeva (VEEV). This makes it worthwhile to examine what the stock has in store.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
